Concepts (225)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tumor Suppressor Protein p53 | 6 | 2024 | 738 | 1.820 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 11 | 2024 | 164 | 1.680 |
Why?
|
| Antigens, Neoplasm | 5 | 2022 | 405 | 1.490 |
Why?
|
| Multiple Myeloma | 4 | 2025 | 216 | 1.470 |
Why?
|
| Cancer Vaccines | 3 | 2022 | 191 | 1.400 |
Why?
|
| Carcinogenesis | 5 | 2021 | 357 | 1.360 |
Why?
|
| Lymphoma | 3 | 2025 | 331 | 1.300 |
Why?
|
| Neoplasms | 15 | 2024 | 2963 | 1.220 |
Why?
|
| Nanoparticles | 3 | 2025 | 292 | 1.020 |
Why?
|
| Myeloid Differentiation Factor 88 | 3 | 2025 | 98 | 1.010 |
Why?
|
| Ubiquitination | 3 | 2023 | 173 | 0.980 |
Why?
|
| RNA, Long Noncoding | 8 | 2021 | 231 | 0.980 |
Why?
|
| Tumor Escape | 2 | 2023 | 63 | 0.920 |
Why?
|
| Herpesvirus 4, Human | 3 | 2023 | 646 | 0.900 |
Why?
|
| B7-H1 Antigen | 3 | 2023 | 132 | 0.890 |
Why?
|
| Vaccines, DNA | 1 | 2025 | 45 | 0.880 |
Why?
|
| Mutation | 8 | 2025 | 6194 | 0.840 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 2 | 2025 | 10 | 0.840 |
Why?
|
| Proto-Oncogene Proteins c-myc | 5 | 2024 | 195 | 0.820 |
Why?
|
| Immunotherapy | 8 | 2024 | 764 | 0.760 |
Why?
|
| Biological Products | 1 | 2025 | 144 | 0.760 |
Why?
|
| Lipids | 1 | 2025 | 566 | 0.680 |
Why?
|
| Breast Neoplasms | 5 | 2021 | 2650 | 0.670 |
Why?
|
| Antibodies, Monoclonal | 2 | 2024 | 1010 | 0.660 |
Why?
|
| Lymphoma, B-Cell | 1 | 2022 | 149 | 0.650 |
Why?
|
| TNF Receptor-Associated Factor 4 | 1 | 2020 | 14 | 0.640 |
Why?
|
| Tumor Microenvironment | 7 | 2024 | 698 | 0.640 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2020 | 29 | 0.640 |
Why?
|
| Biomarkers, Tumor | 11 | 2025 | 1617 | 0.640 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2020 | 58 | 0.630 |
Why?
|
| Herbicides | 1 | 2019 | 13 | 0.610 |
Why?
|
| Cell Line, Tumor | 11 | 2025 | 3694 | 0.610 |
Why?
|
| DNA | 1 | 2025 | 1440 | 0.600 |
Why?
|
| NF-kappa B | 1 | 2021 | 449 | 0.580 |
Why?
|
| Glycine | 1 | 2019 | 166 | 0.560 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2019 | 237 | 0.560 |
Why?
|
| Prognosis | 18 | 2025 | 4953 | 0.540 |
Why?
|
| Sarcoma | 1 | 2019 | 211 | 0.520 |
Why?
|
| Animals | 21 | 2025 | 34402 | 0.480 |
Why?
|
| MicroRNAs | 7 | 2021 | 895 | 0.470 |
Why?
|
| Mice | 12 | 2025 | 18479 | 0.450 |
Why?
|
| Glioma | 1 | 2019 | 498 | 0.440 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 639 | 0.410 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2021 | 2004 | 0.410 |
Why?
|
| Humans | 49 | 2025 | 131781 | 0.390 |
Why?
|
| Liposomes | 2 | 2025 | 200 | 0.380 |
Why?
|
| Lung Neoplasms | 4 | 2024 | 1542 | 0.370 |
Why?
|
| Antineoplastic Agents | 4 | 2025 | 1811 | 0.360 |
Why?
|
| Proteolysis | 2 | 2025 | 195 | 0.360 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2025 | 460 | 0.350 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2023 | 138 | 0.330 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 1297 | 0.320 |
Why?
|
| Sequence Analysis, RNA | 3 | 2024 | 420 | 0.320 |
Why?
|
| Single-Cell Analysis | 3 | 2024 | 364 | 0.310 |
Why?
|
| Cytoskeletal Proteins | 2 | 2020 | 279 | 0.300 |
Why?
|
| Plasma Cells | 2 | 2025 | 56 | 0.270 |
Why?
|
| B-Lymphocytes | 3 | 2024 | 528 | 0.240 |
Why?
|
| Nasopharyngeal Neoplasms | 3 | 2020 | 62 | 0.240 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2025 | 999 | 0.230 |
Why?
|
| Cell Movement | 4 | 2021 | 886 | 0.220 |
Why?
|
| DNA Mismatch Repair | 1 | 2024 | 45 | 0.220 |
Why?
|
| Neoplasm Metastasis | 3 | 2021 | 711 | 0.210 |
Why?
|
| Paraproteinemias | 1 | 2024 | 21 | 0.210 |
Why?
|
| Down-Regulation | 3 | 2020 | 659 | 0.200 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 140 | 0.200 |
Why?
|
| Female | 17 | 2025 | 71221 | 0.190 |
Why?
|
| Lymphoma, T-Cell | 1 | 2023 | 64 | 0.190 |
Why?
|
| Gene Expression Profiling | 4 | 2025 | 1835 | 0.190 |
Why?
|
| Immune Evasion | 1 | 2023 | 39 | 0.190 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2022 | 18 | 0.190 |
Why?
|
| Disease Progression | 4 | 2025 | 2221 | 0.190 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2022 | 23 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 130 | 0.170 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2023 | 156 | 0.170 |
Why?
|
| Y-Box-Binding Protein 1 | 1 | 2021 | 10 | 0.170 |
Why?
|
| HEK293 Cells | 2 | 2021 | 810 | 0.170 |
Why?
|
| Killer Cells, Natural | 1 | 2024 | 344 | 0.170 |
Why?
|
| RNA, Antisense | 1 | 2021 | 35 | 0.170 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2021 | 28 | 0.170 |
Why?
|
| Tumor Hypoxia | 1 | 2021 | 7 | 0.170 |
Why?
|
| Cell Proliferation | 4 | 2021 | 2483 | 0.170 |
Why?
|
| Molecular Mimicry | 1 | 2021 | 23 | 0.170 |
Why?
|
| Transcriptome | 3 | 2025 | 1150 | 0.170 |
Why?
|
| Hydrazines | 1 | 2020 | 30 | 0.170 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2020 | 294 | 0.160 |
Why?
|
| Receptors, CXCR4 | 1 | 2021 | 71 | 0.160 |
Why?
|
| Karyopherins | 1 | 2020 | 36 | 0.160 |
Why?
|
| Cell Membrane | 1 | 2023 | 464 | 0.160 |
Why?
|
| Stathmin | 1 | 2020 | 1 | 0.160 |
Why?
|
| RNA-Binding Proteins | 2 | 2021 | 548 | 0.160 |
Why?
|
| Adenosine | 1 | 2021 | 124 | 0.160 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 388 | 0.160 |
Why?
|
| Mutation, Missense | 1 | 2025 | 932 | 0.160 |
Why?
|
| Macrophages | 1 | 2024 | 661 | 0.160 |
Why?
|
| GTPase-Activating Proteins | 1 | 2020 | 86 | 0.160 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 363 | 0.160 |
Why?
|
| Antigen Presentation | 1 | 2020 | 118 | 0.160 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2019 | 20 | 0.160 |
Why?
|
| Triazoles | 1 | 2020 | 144 | 0.160 |
Why?
|
| Cytoskeleton | 1 | 2020 | 167 | 0.150 |
Why?
|
| Neovascularization, Pathologic | 1 | 2021 | 234 | 0.150 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2019 | 51 | 0.150 |
Why?
|
| Microfilament Proteins | 1 | 2021 | 272 | 0.150 |
Why?
|
| Splenomegaly | 1 | 2019 | 32 | 0.150 |
Why?
|
| Cell Adhesion Molecules | 1 | 2020 | 227 | 0.150 |
Why?
|
| Chromosomes, Human, X | 1 | 2020 | 155 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 1356 | 0.150 |
Why?
|
| Mammary Glands, Human | 1 | 2019 | 81 | 0.150 |
Why?
|
| Cellular Reprogramming | 1 | 2020 | 127 | 0.150 |
Why?
|
| Water Pollutants, Chemical | 1 | 2019 | 37 | 0.150 |
Why?
|
| Enzyme Activation | 1 | 2020 | 590 | 0.150 |
Why?
|
| Fibroblast Growth Factors | 1 | 2020 | 169 | 0.140 |
Why?
|
| Peptides | 1 | 2022 | 835 | 0.140 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2020 | 329 | 0.140 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2021 | 152 | 0.130 |
Why?
|
| Stomach Neoplasms | 2 | 2020 | 579 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 327 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2023 | 759 | 0.130 |
Why?
|
| DNA Damage | 1 | 2020 | 527 | 0.130 |
Why?
|
| Phosphorylation | 1 | 2020 | 1571 | 0.120 |
Why?
|
| Peptide Fragments | 1 | 2020 | 781 | 0.120 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 329 | 0.120 |
Why?
|
| Adult | 8 | 2025 | 31710 | 0.120 |
Why?
|
| Rituximab | 3 | 2022 | 174 | 0.120 |
Why?
|
| Energy Metabolism | 1 | 2020 | 785 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 824 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2021 | 260 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 632 | 0.110 |
Why?
|
| Mice, Nude | 3 | 2020 | 714 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 3 | 2021 | 646 | 0.110 |
Why?
|
| Nuclear Proteins | 1 | 2020 | 1226 | 0.100 |
Why?
|
| Male | 11 | 2025 | 65290 | 0.100 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 1844 | 0.090 |
Why?
|
| ROC Curve | 2 | 2025 | 623 | 0.090 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 2 | 2021 | 27 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2022 | 173 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2020 | 2438 | 0.080 |
Why?
|
| Prednisone | 2 | 2022 | 244 | 0.080 |
Why?
|
| Vincristine | 2 | 2022 | 194 | 0.080 |
Why?
|
| Middle Aged | 7 | 2025 | 28897 | 0.080 |
Why?
|
| Aged | 6 | 2025 | 21263 | 0.080 |
Why?
|
| 3' Untranslated Regions | 2 | 2020 | 164 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 4767 | 0.080 |
Why?
|
| Doxorubicin | 2 | 2022 | 301 | 0.080 |
Why?
|
| Dexamethasone | 2 | 2021 | 262 | 0.070 |
Why?
|
| Cyclophosphamide | 2 | 2022 | 441 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 3416 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2021 | 832 | 0.070 |
Why?
|
| RNA, Viral | 2 | 2020 | 512 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 2 | 2020 | 1020 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2020 | 12997 | 0.070 |
Why?
|
| Brain | 1 | 2019 | 3236 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 1260 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 934 | 0.060 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2024 | 11 | 0.050 |
Why?
|
| Genes, myc | 1 | 2024 | 95 | 0.050 |
Why?
|
| Apoptosis | 2 | 2020 | 1860 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2023 | 159 | 0.050 |
Why?
|
| Immunity | 1 | 2023 | 179 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2025 | 296 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2025 | 6916 | 0.040 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2021 | 7 | 0.040 |
Why?
|
| A549 Cells | 1 | 2021 | 49 | 0.040 |
Why?
|
| Phosphatidylinositols | 1 | 2021 | 31 | 0.040 |
Why?
|
| Silicon Dioxide | 1 | 2021 | 31 | 0.040 |
Why?
|
| Breast Diseases | 1 | 2021 | 38 | 0.040 |
Why?
|
| Polymerization | 1 | 2020 | 14 | 0.040 |
Why?
|
| Heterografts | 1 | 2021 | 195 | 0.040 |
Why?
|
| Germinal Center | 1 | 2020 | 37 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 213 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2023 | 577 | 0.040 |
Why?
|
| Adenine | 1 | 2021 | 123 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 2021 | 210 | 0.040 |
Why?
|
| Cytarabine | 1 | 2020 | 101 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2020 | 228 | 0.040 |
Why?
|
| Etoposide | 1 | 2020 | 117 | 0.040 |
Why?
|
| X Chromosome Inactivation | 1 | 2020 | 60 | 0.040 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2019 | 5 | 0.040 |
Why?
|
| Mouth Neoplasms | 1 | 2020 | 98 | 0.040 |
Why?
|
| Transfection | 1 | 2021 | 960 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 792 | 0.040 |
Why?
|
| beta Catenin | 1 | 2020 | 209 | 0.040 |
Why?
|
| Cadherins | 1 | 2020 | 178 | 0.040 |
Why?
|
| Piperidines | 1 | 2021 | 231 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 803 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 989 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2021 | 4682 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 199 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2020 | 418 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2021 | 329 | 0.030 |
Why?
|
| Machine Learning | 1 | 2022 | 375 | 0.030 |
Why?
|
| Methotrexate | 1 | 2020 | 342 | 0.030 |
Why?
|
| Smoking | 1 | 2023 | 927 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2020 | 338 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 810 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2020 | 752 | 0.030 |
Why?
|
| Proteomics | 1 | 2022 | 609 | 0.030 |
Why?
|
| Autophagy | 1 | 2021 | 424 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 2020 | 248 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2021 | 1489 | 0.030 |
Why?
|
| Cytokines | 1 | 2023 | 1348 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 373 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 1322 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2020 | 489 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2020 | 1522 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2024 | 1964 | 0.030 |
Why?
|
| Protein Binding | 1 | 2020 | 1711 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 2020 | 557 | 0.030 |
Why?
|
| Cell Line | 1 | 2020 | 2606 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 1746 | 0.030 |
Why?
|
| Algorithms | 1 | 2022 | 1685 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2021 | 557 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2023 | 1788 | 0.030 |
Why?
|
| Models, Biological | 1 | 2019 | 1395 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2025 | 17667 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2993 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1101 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 3451 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2023 | 5122 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2023 | 4684 | 0.020 |
Why?
|
| Genomics | 1 | 2020 | 1626 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 5297 | 0.020 |
Why?
|
| Young Adult | 1 | 2020 | 10102 | 0.010 |
Why?
|
| Adolescent | 1 | 2020 | 20994 | 0.010 |
Why?
|
| Child | 1 | 2020 | 26316 | 0.010 |
Why?
|